The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
FDA withdrawal of panobinostat for the treatment of R/R MM
On November 30, 2021, it was announced that the U.S. Food and Drug Administration (FDA) will withdraw the approval of panobinostat for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).1
Panobinostat was first granted accelerated approval in combination with bortezomib and dexamethasone in February 2015 for patients who had previously received ≥2 prior regimens, including bortezomib and an immunomodulatory agent.2 The approval was based on the progression-free survival results from the phase III PANORAMA1 study (NCT01023308), which have previously been published on the Multiple Myeloma Hub. However, to maintain the approval, further adequate and well-controlled clinical studies were required to verify the clinical benefit of panobinostat. As it was not possible to complete these required post-approval clinical studies, the approval has been withdrawn.1
Panobinostat continues to be investigated in a phase II trial (NCT02506959) in combination with high-dose gemcitabine, busulfan, and melphalan prior to autologous stem cell transplantation in patients with R/R MM.3,4
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content